Literature DB >> 20208391

LKM-1 sera from autoimmune hepatitis patients that recognize ERp57, carboxylesterase 1 and CYP2D6.

Ryo Komurasaki1, Susumu Imaoka, Naomichi Tada, Kazushi Okada, Shuhei Nishiguchi, Yoshihiko Funae.   

Abstract

Liver kidney microsomal antibody type 1 (LKM-1) is a diagnostic marker for autoimmune hepatitis type 2 (AIH-2). Characterization of LKM autoantibodies of patients with AIH-2 demonstrated that a proportion of LKM sera contains autoantibodies which recognize one or more small linear epitopes on cytochrome P450, CYP2D6, an enzyme of drug metabolism pathways. The identification and epitope mapping of antigens involved in autoimmune diseases are important in understanding the mechanisms triggering autoimmunity and providing guidance for designing immunomodulatory therapy. In this study, several proteins recognized by LKM-1-positive sera in rat and human hepatic microsomes were analyzed by MALDI-TOF-MS after separation with ion-exchange chromatography or two-dimensional polyacrylamide gel electrophoresis. We identified these proteins as ERp57 and carboxylesterase 1 (CES1) as well as CYP2D6. Epitopes in ERp57 and CES1 recognized by LKM-1-positive serum were investigated by enzyme-linked immunosorbent assay (ELISA) with protease-digested peptides of ERp57 and CES1. The peptides comprising amino acids 105-129 of ERp57 and 558-566 of CES1 were specifically recognized by the serum. The epitopes in EPp57 and CES1 recognized by LKM-1-positive sera were homologous with those in hepatitis C virus (HCV). Viral infection of such as HCV may thus possibly trigger autoimmune hepatitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20208391     DOI: 10.2133/dmpk.25.84

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  10 in total

Review 1.  Vascular thiol isomerases.

Authors:  Robert Flaumenhaft; Bruce Furie
Journal:  Blood       Date:  2016-06-29       Impact factor: 22.113

Review 2.  Pathogens and autoimmune hepatitis.

Authors:  U Christen; E Hintermann
Journal:  Clin Exp Immunol       Date:  2018-10-07       Impact factor: 4.330

3.  Discovery of serum protein biomarkers in rheumatoid arthritis using MALDI-TOF-MS combined with magnetic beads.

Authors:  Xiaoxue Zhang; Zhaolin Yuan; Bo Shen; Min Zhu; Chibo Liu; Wei Xu
Journal:  Clin Exp Med       Date:  2011-09-16       Impact factor: 3.984

Review 4.  Immunogenic cell stress and death.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Claudia Galassi; Laurence Zitvogel
Journal:  Nat Immunol       Date:  2022-02-10       Impact factor: 25.606

Review 5.  Endoplasmic Reticulum Stress Interacts With Inflammation in Human Diseases.

Authors:  Stewart Siyan Cao; Katherine L Luo; Lynn Shi
Journal:  J Cell Physiol       Date:  2016-02       Impact factor: 6.384

6.  Autoimmune hepatitis related autoantibodies in children with type 1 diabetes.

Authors:  Abdulrahman A Al-Hussaini; Musa D Alzahrani; Ahmed S Alenizi; Nimer M Suliman; Mannan A Khan; Sahar A Alharbi; Aziz A Chentoufi
Journal:  Diabetol Metab Syndr       Date:  2014-03-17       Impact factor: 3.320

Review 7.  Coherent somatic mutation in autoimmune disease.

Authors:  Kenneth Andrew Ross
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

Review 8.  Mechanisms of Translocation of ER Chaperones to the Cell Surface and Immunomodulatory Roles in Cancer and Autoimmunity.

Authors:  Valerie R Wiersma; Marek Michalak; Trefa M Abdullah; Edwin Bremer; Paul Eggleton
Journal:  Front Oncol       Date:  2015-01-29       Impact factor: 6.244

9.  Exploring the cross talk between ER stress and inflammation in age-related macular degeneration.

Authors:  Samira Kheitan; Zarrin Minuchehr; Zahra-Soheila Soheili
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

Review 10.  Autoantibodies in Autoimmune Hepatitis: Can Epitopes Tell Us about the Etiology of the Disease?

Authors:  Urs Christen; Edith Hintermann
Journal:  Front Immunol       Date:  2018-02-16       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.